

CORRECTION

Open Access



Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

C. Festuccia^{1*}, A. Mancini², A. Colapietro², G. L. Gravina^{2,3}, F. Vitale⁴, F. Marampon³, S. Delle Monache⁵, S. Pompili⁶, L. Cristiano⁷, A. Vetuschi⁶, V. Tombolini⁸, Y. Chen⁹ and T. Mehrling¹⁰

Erratum

The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales.

This has now been corrected, and can be seen ahead and in the original article [1].

Author details

¹Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ²Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ³Division of Radiotherapy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁴Division of Neurosciences, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁵Division of Applied Biology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁶Division of Human Anatomy, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy. ⁷Laboratory of Applied Biology, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. ⁸Division of Radiotherapy, Department of Experimental Medicine, University of Rome "La Sapienza", Rome, Italy. ⁹Northlake International LLC, Pleasanton, CA, USA. ¹⁰Mundipharma-EDO GmbH, Basel, Switzerland.

Received: 8 March 2018 Accepted: 8 March 2018

Published online: 14 March 2018

Reference

1. Festuccia C, et al. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. *J Hematol Oncol*. 2018;11:32.

* Correspondence: claudio.festuccia@univaq.it

¹Laboratory of Radiobiology, Department of Applied Clinical Sciences and Biotechnologies, University of L'Aquila, L'Aquila, Italy

